Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 03:33 ET | Source: CONNECTA Therapeutics

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

CONNECTA Therapeutics initiates Phase IIa trial advancing treatments for rare CNS disorders, strengthening its clinical pipeline and development strategy.